Log In
BCIQ
Print this Print this
 

Colcrys, colchicine

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionLow-dose formulation of colchicine
Molecular Target Tubulin
Mechanism of ActionMicrotubule polymerization inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationHyperuricemia / gout
Indication DetailsTreat and prevent gout flares; Treat gout
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

$800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/12/2015

Undisclosed

Undisclosed

Undisclosed

06/11/2012

Undisclosed

$800.0M

Undisclosed

Get a free BioCentury trial today